To the Editors, Vedolizumab is a gut-selected humanized α4β7 integrin antibody, which reduces intestinal inflammation by inhibiting lymphocyte migration to the gut. Recently, vedolizumab has been increasingly used in the treatment of moderately to severely active ulcerative colitis (UC). Vedolizumab safety assessment showed a high safety profile with low incidence rates of serious infections, malignancy events, and <5% of infusion-related reactions.1 The results from the vedolizumab GEMINI long-term safety (LTS) study have further established its safety.2 Here, we report a case of acute allergic reaction following the fifth infusion of vedolizumab in a patient with refractory UC. A 26-year-old woman with a history of UC for 10 years, who was refractory to corticosteroids, received 4 doses of vedolizumab (300 mg) for 15 weeks. The patient experienced severe abdominal colic, shortness of breath, dizziness, and numbness in the limbs after 5 minutes of intravenous (IV) administration of fifth vedolizumab...